But if we can’t ban pharmaceutical ads, we can at least rein them in. Policymakers can play an integral role in addressing the manipulative advertising practices rampant in the industry, while still ...
Immunovant said on Wednesday its experimental treatment for a type of chronic muscle weakness improved patients' symptoms and that it aimed to use the data to accelerate the development of a newer ...
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
1d
News Medical on MSNEfficient development of drugs with fewer miceNew active ingredients such as antibodies are usually tested individually in laboratory animals. Researchers at UZH have now ...
The convergence of AI and drug delivery is opening new frontiers in precision medicine. AI-powered predictive modeling is ...
1d
Clinical Trials Arena on MSNAstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIUK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
1d
News-Medical.Net on MSNAdding curcumin boosts the efficacy of bedaquiline in combating M. abscessus infectionsMycobacterium abscessus is a fast-growing, pathogenic mycobacteria that can cause lung infections, and people who have ...
Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...
The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...
The field of cancer treatment has long struggled with the immense costs and time-consuming nature of drug development.
The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...
Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results